medigraphic.com

2009, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2009; 47 (2)

The Hyperlipidemia Diagnosis Based in Phenotype

Aude-Rueda O, Aguilar-Nungaray G, Villa-Romero A, Cruz-Bautista I, Aguilar-Salinas CA

Language: Spanish
References: 39
Page: 121-128
PDF size: 180.31 Kb.


ABSTRACT

Objective: to describe the different clinical profiles of patients with dyslipidemia based on lipid phenotype, in an urban setting.
Methods: a survey was carried out among college students and general population. A structured interview was conducted. Blood was drawn for glucose and lipid profile from subjects considered to be healthy.
Results: we included 1286 subjects. They were grouped by socioeconomic status (low income = 437, medium income = 162 and high income = 133) and 554 college students who had lived in the area for at least one year. Women composed 61 % of the cohort; 86 % of the cases were studied after an overnight fasting period. The prevalent lipid phenotype was hypoalphalipoproteinemia, followed by mixed hyperlipidemia. Among medium income group, isolated hypercholesterolemia was a common finding. High fasting glucose and low c-HDL were observed among the low income group. Male gender and age are predictors for hypercholesterolemia. The BMI is the only identified predictor of hypertriglyceridemia (OR = 10.089). We identified that age › 55-year old (OR = 2.6), male gender (OR = 1.6), and sedentary life (OR = 1.35), were predictors of hypoalphalipoproteinemia.
Conclusion: the most common lipid phenotype was hypoalphalipoproteinemia.


REFERENCES

  1. Dirección General de Epidemiología, México. Secretaría de Salud, 2004.

  2. Meaney E, Lara-Esqueda A, Ceballos-Reyes GM, Asbun J, Vela A, Martínez-Marroquín Y, et al. Cardiovascular risk factors in the urban Mexican population: The FRIMEX Study. Public Health 2007;121(5):378-384.

  3. Sánchez-Castillo CP, Velásquez-Monroy O, Lara-Esqueda A, Berber A, Sepúlveda J, Tapia-Conyer R, et al. Diabetes and hypertension increases in a society with abdominal obesity: results of the Mexican National Health Survey 2000. Public Health Nutr 2005;8(1):53-60.

  4. Lerman IG, Villa AR, Martínez CL, Cervantes-Turrubiatez L, Aguilar-Salinas CA, Wong B, et al. The prevalence of diabetes and associated coronary risk factors in urban and rural older Mexican populations. J Am Geriatr Soc 1998;46:1387-1395.

  5. Muñoz-de Chávez MA, Chávez-Villasana, M, Chávez-Muñoz, Eichin I. Sale of street food in Latin America. The Mexican case; joy or jeopardy? World Rev Nutr Diet 2000;86:138-154.

  6. Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, D’Agostino RB, et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 2007;116(5):480-488.

  7. Macdiarmid JI, Vail A, Cade JE, Blundell JE. The sugar-fat relationship revisited: differences in consumption between men and women of varying BMI. Int J Obes Relat Metab Disord 1998;22(11):1053-1061.

  8. Fager G, Wilklung O. Cholesterol reduction and clinical benefit. Are there limits to our expectations? Artherioscler Thromb Vasc Biol 1997;17(12):3527-3533.

  9. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation 2004;109(4):551-556.

  10. Alberti KG, Zimmet P, Shaw J; The IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366 (9491):1059-1062.

  11. García-García G, Avilés-Gómez R, Luquín-Arellano VH, Padilla-Ochoa R, Lepe-Murillo L, Ibarra-Hernández M, et al. Cardiovascular risk factors in the Mexican population. Ren Fail 2006;28(8):677-687.

  12. Wei M, Mitchell BD, Haffner SM, Stern MP. Effects of cigarette smoking, diabetes, high cholesterol, and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans. The San Antonio Heart Study. Am J Epidemiol 1996;44(11):1058-1065.

  13. Quibrera-Infante R, Hernández-Rodríguez HG, Aradillas-García C, González- Rodríguez S, Calles-Escandón J. Prevalences of diabetes, glucose intolerance, hyperlipemia and risk factors as a function of socioeconomic level. Rev Invest Clin 1994;46(1):25-36.

  14. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Ríos-Torres JM, Franco A, et al. High prevalence of metabolic syndrome in Mexico. Arch Med Res 2004;35(1):76-81.

  15. Yamamoto-Kimura L, Zamora-González J, Huerta-Alvarado S, Fajardo-Gutiérrez A, Cardoso-Saldaña G, Posadas-Romero C. High blood pressure and cardiovascular risk factors in an adult population of Mexico City. Characteristics of the studied population. Arch Med Res 1996;27(2):213-222.

  16. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos-Torres JM, Gómez-Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation-wide survey. J Lipid Res 2001;42(8):1298-1307.

  17. Lara A, Rosas M, Pastelín G, Aguilar C, Attié F, Velázquez-Monroy O. Hypercholesterolemia and hypertension in Mexico: urban conjunctive consolidation with obesity, diabetes and smoking. Arch Cardiol Mex 2004;74(3):231-245. Spanish. Erratum in: Arch Cardiol Mex 2005;75(2):221.

  18. Posadas-Romero C, Tapia-Conyer R, Lerman-Garber I, Zamora-González J, Cardoso-Saldaña G, Salvatierra-Izaba B, et al. Cholesterol levels and prevalence of hypercholesterolemia in a Mexican adult population. Atherosclerosis 1995;118(2):275-284.

  19. Posadas-Romero C, Sepúlveda J, Tapia-Conyer R, Magos C, Cardoso-Saldaña G, Zamora-González J, et al. Values of serum cholesterol in the Mexican population. Salud Publica Mex 1992;34(2):157-167.

  20. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-2497.

  21. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26(Suppl 1):S5-S20.

  22. The American Association of Clinical Endocrinologist (AACE) 2000. Lipid guidelines. Endocr Pract 2006:164-213.

  23. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart diseases in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Blood Press 1998;7(5-6):262-269.

  24. McPherson R, Frohlich J, Fodor G, Genest J; Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement —recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22(11):913-97.

  25. Farmer JA. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Atheroscler Rep 2007;9(2):162-168.

  26. National Heart Lung and Blood Institute. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. Disponible en http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf

  27. Singh RB, Beegom R, Mehta AS, Niaz MA, De AK, Mitra RK, et al. Social class, coronary risk factors and undernutrition, a double burden of diseases, in women during transition, in five Indian cities. Int J Cardiol 1999;69(2):139-147.

  28. Aguilar-Salinas CA, Huertas A, Tusi’r TM, Gómez- Pérez FJ, Rull JA Hiperlipidemia familiar combinada: caracterización en población mexicana. Rev End Nutr 2002;10(2):58-62.

  29. Barquera S, Flores M, Olaiz-Fernández G, Monterrubio E, Villalpando S, Gonzalez C, et al. Dyslipidemias and obesity in México. Salud Publica Mex 2007;49(Suppl 3):S338-S347.

  30. Windler E, Schöffauer M, Zyriax BC. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diab Vasc Dis Res 200;47(2):136-142.

  31. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17(1): 107-113.

  32. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B HDL-cholesterol as a marker of coronary heart disease risk: the Quebec Cardiovascular Study. Atherosclerosis 2000;153(2):263-272.

  33. Gordon T, Castelli, WP, Hjartland, MC, Kannel, WD, Dawber, TR. High density lipoprotein as a protective factor against coronary artery disease. The Framingham Study. Am J Med 1977;62(5):707-714.

  34. Genest JJ, Martin-Munley, SS, McNamara, JR, Ordovas JM, Jenner J, Myers RH, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85(6):2025-2033.

  35. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation 1992;86(3):839-848.

  36. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública; 2006.

  37. Lloyd-Jones D, Wilson P, Larson M, Leip E, Beiser A, et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 2003;163(16):1966-1972.

  38. Robin-S, Bloomfield-Rubins H, Faas F, Schaefer E, Elam M, Anderson J, Collins D. Insuline resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;268(5):1513-1517.

  39. Aguilar-Salina C, Gómez-Diaz R, Gómez-Pérez FJ. Dislipidemias. De lo clínico a lo molecular: México: Intersistemas; 2008.




2020     |     www.medigraphic.com